1. Home
  2. WVE vs DCBO Comparison

WVE vs DCBO Comparison

Compare WVE & DCBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • DCBO
  • Stock Information
  • Founded
  • WVE 2012
  • DCBO 2016
  • Country
  • WVE Singapore
  • DCBO Canada
  • Employees
  • WVE N/A
  • DCBO N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • DCBO
  • Sector
  • WVE Health Care
  • DCBO
  • Exchange
  • WVE Nasdaq
  • DCBO Nasdaq
  • Market Cap
  • WVE 915.6M
  • DCBO 893.7M
  • IPO Year
  • WVE 2015
  • DCBO 2020
  • Fundamental
  • Price
  • WVE $9.76
  • DCBO $31.54
  • Analyst Decision
  • WVE Strong Buy
  • DCBO Strong Buy
  • Analyst Count
  • WVE 16
  • DCBO 5
  • Target Price
  • WVE $20.00
  • DCBO $42.20
  • AVG Volume (30 Days)
  • WVE 1.6M
  • DCBO 84.1K
  • Earning Date
  • WVE 07-30-2025
  • DCBO 08-08-2025
  • Dividend Yield
  • WVE N/A
  • DCBO N/A
  • EPS Growth
  • WVE N/A
  • DCBO 33.51
  • EPS
  • WVE N/A
  • DCBO 0.69
  • Revenue
  • WVE $93,946,000.00
  • DCBO $230,502,000.00
  • Revenue This Year
  • WVE N/A
  • DCBO $11.63
  • Revenue Next Year
  • WVE $4.55
  • DCBO $9.49
  • P/E Ratio
  • WVE N/A
  • DCBO $45.57
  • Revenue Growth
  • WVE N/A
  • DCBO 15.11
  • 52 Week Low
  • WVE $5.04
  • DCBO $25.50
  • 52 Week High
  • WVE $16.74
  • DCBO $53.86
  • Technical
  • Relative Strength Index (RSI)
  • WVE 72.03
  • DCBO 58.12
  • Support Level
  • WVE $8.40
  • DCBO $31.23
  • Resistance Level
  • WVE $9.03
  • DCBO $32.36
  • Average True Range (ATR)
  • WVE 0.55
  • DCBO 1.14
  • MACD
  • WVE 0.06
  • DCBO 0.04
  • Stochastic Oscillator
  • WVE 98.53
  • DCBO 58.86

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

Share on Social Networks: